Introducing Walter Tamulis, Senior Staff Engineer, MSAT
![](https://antheia.bio/wp-content/uploads/2024/02/Walter-Headshot-1024x768.webp)
Antheia’s recent commercial breakthrough required the effort of many technical experts who contributed countless hours of hard work. In today’s blog, we are pleased to introduce Walter Tamulis, Senior Staff Engineer of MSAT, a key member of the operations team who was essential in executing our first 116,000L scale run of thebaine and subsequent validation runs. We sat down to speak with Walter to ask him about his background and what inspires him at Antheia: You bring a wealth of experience in pharma manufacturing to the team, from pilot scale to commercial scale manufacturing. For those who don’t know you, let’s start with you telling us a little about yourself and your background. I studied molecular biology at the lab bench in graduate school, but my first industry experience was actually in large scale manufacturing of monoclonal antibodies for Genentech. That’s where I started growing a passion for the science of manufacturing and scale up, which has endured across my 17 years in bioprocess industries. From manufacturing pharmaceutical biologics with Genentech, I moved on to developing advanced biofuels technologies with BP and DuPont, industrializing enzyme production processes with BASF, and more recently, scaling-up precision fermentation with Zymergen. Now, I am enabling the commercialization of cutting-edge synthetic biology technologies with Antheia. My experience has really been about straddling different scales of technology with different teams and tech transferring processes within and across companies, including owned and operated facilities and contract manufacturers. I’ve always loved seeing things happen for the first time on a large scale, and at Antheia, I do just that – working with the right partners, facilities, and technologies to ensure the scaleup and manufacturability of our products is feasible. What made you say “yes” to Antheia initially and what inspires you about the work you do here? I was introduced to Antheia by Zack McGahey, our COO whom I had worked with previously at Zymergen. As soon as we had our first conversation about Antheia, I really understood the power of the technology and the potential it holds for sustainable and renewable manufacturing. I found that incredibly inspiring and I was immediately interested by the opportunity to both apply my experience in the industry and work on something that is meaningful to me on a personal level, since I believe that sustainability and renewability in manufacturing is one of the most dynamic things we can do to work within our resource constraints while improving our planet. When I reconnected with Zack, the technology had just matured and was ready to move into commercial production, so I was fortunate to join right as the operations team was beginning to ramp up. Once I had a chance to meet the team, I was really sold by the work ethic, scientific excellence, and focus shared by the entire company – it was an easy decision. Since then, I’ve been a part of that critical moment where the rubber hits the road as we actively commercialize our first products. It’s been an exciting time to be a part of this team. We know you’ve had an incredibly busy season – can you share what your work looks like, as the rubber has hit the road, so to speak? My work is pretty project based, focusing on the target product that we’re working on at any given point. Now that Antheia’s first product, thebaine, has debuted, we are hard at work on moving our second and third products to commercial scale while our R&D team continues to develop and progress products that are still moving through our pipeline. These products are in various stages of development and commercialization, which means my role is overseeing the transfer of those technologies – at any stage they’re in, whether that be pilot, demonstration, or commercial – to our external sites, currently both abroad for commercial and in the U.S. for some of our pilot-scale operations. In addition to our commercial and customer engagement efforts, these tech transfers and scaled runs are critical to our forward momentum as a KSM and API producer. It’s exciting to be part of this progress as we move toward validating our product with customers and passing the final hurdles with regulatory bodies. In terms of my day-to-day, I spend a lot of time at these partner sites, working closely with our third-party manufacturing teams and liaising between Antheia’s R&D, operations, and commercial teams. One week I may be evaluating a potential facility in anticipation of scale-up and commercialization and the next week I’m supporting the execution of commercial production runs at an established partner. These are tangible, on-site projects with capital expenditures that require up-close monitoring to ensure functionality, which means that I’m constantly collaborating with people at manufacturing sites all over the world. The first successful commercial run of thebaine was a massive milestone for Antheia and then shortly after, Antheia completed its validation campaign. These were huge feats for the operations team, and you specifically spent a lot of time with our partner in Europe to make that happen. Can you share more about that experience? Absolutely. From an engineering perspective, quite a few complex capital expenditure (CAPEX) projects were required at our partner contract manufacturing organization (CMO) to enable these first manufactured batches of thebaine. In the 12 months leading up to actual execution, we had to design, order, install, and commission equipment while working closely with the CMO engineering team to ensure on-time delivery and to meet all operational and safety requirements. We also identified projects to increase efficiency and reduce operational costs, alongside modeling the techno-economics of our processes. During the execution of our first commercial validation runs, I represented Antheia at our CMO as our person-in-plant. In this role, I helped maintain timelines and ensure that Antheia’s expectations of operational execution, equipment reliability, and product quality were met. I was the eyes and ears for Antheia onsite at our CMO for weeks and months at a time, and it meant wearing multiple hats, monitoring
Forbes Sustainability Leaders Summit: Antheia’s CEO on Transforming Supply Chains
![Forbes Sustainability Leaders Summit](https://antheia.bio/wp-content/uploads/2023/09/Forbes-Sustainability-Leaders-Summit.jpg)
Antheia joined some of the industry’s most notable thought leaders at the prestigious Forbes Sustainability Leaders Summit, which gathered on September 20 in New York City to discuss insights, innovations, and visions for a more sustainable future.
The Road to Commercialization
![](https://antheia.bio/wp-content/uploads/2023/08/Platform_IndustrialFermentation-1-3-1024x683.webp)
Antheia’s Chief Operations Officer Zack McGahey offers his perspective on the company’s most recent commercial milestone – a successful full-scale fermentation run of its first product at 116,000L.
Engineered Yeast Could Reduce Drug Shortages
![](https://antheia.bio/wp-content/uploads/2023/07/Industrial-Fermentation-2-2-1024x683.webp)
Brewer’s yeast engineered with synthetic biology to produce drugs or raw materials could transform pharmaceutical supply chains.
Leveraging Synthetic Biology for Resilient Pharma Supply Chains and Accessible Medicines
![](https://antheia.bio/wp-content/uploads/2023/05/Leveraging-Synthetic-Biology-for-Resilient-Pharma-Supply-Chains-and-Accessible-Medicines.png)
Antheia was founded in 2015 by Dr. Christina Smolke, CEO and Dr. Kristy Hawkins, CSO and is based in Menlo Park, California. Antheia’s co-founders are pioneers in the fields of synthetic biology and metabolic engineering and are applying these technologies to transform pharmaceutical supply chains in order to better support the needs of 21st century healthcare.
Advancing the U.S. Bioeconomy and Building Resilient Pharmaceutical Supply Chains
![Advancing the U.S. Bioeconomy and Building Resilient Pharmaceutical Supply Chains](https://antheia.bio/wp-content/uploads/2023/05/Advancing-the-U.S.-Bioeconomy-and-Building-Resilient-Pharmaceutical-Supply-Chains.png)
We continue to see the U.S. government setting policy priorities that underscore the importance of both building a robust American bioeconomy and strengthening domestic pharmaceutical supply chains – two core pillars of Antheia’s business and technology.
Synthetic Chemistry in Pharma
![](https://antheia.bio/wp-content/uploads/2023/05/Synthetic-Chemistry-in-Pharma.png)
Synthetic chemistry is an essential part of drug development, opening the door for scientists to create complex small molecules with specific properties. Small molecule drugs – including household staples like aspirin and acetaminophen – currently make up the bulk of approved pharmaceuticals to date.
Antheia CEO on How Biomanufacturing can De-Risk Pharmaceutical Production
![](https://antheia.bio/wp-content/uploads/2022/11/Frame-1.png)
In a recent Q&A with European Pharmaceutical Manufacturer Antheia CEO and co-founder Dr. Christina Smolke discussed how latency and variability within agricultural supply chains remains the number one challenge in the pharmaceutical-grade production…
Antheia Announces New Financing and Plans to Construct Pilot Plant Facility for Biomanufacturing
![Press-Release-Thumbnail](https://antheia.bio/wp-content/uploads/2024/01/Press-Release-Thumbnail_Compressed-1024x768.webp)
Antheia, a synthetic biology company enabling next-generation plant-inspired medicines, today announced $40 million in venture debt financing from Oxford Finance LLC and Silicon Valley Bank, alongside plans to construct a new pilot scale biomanufacturing facility.
Biomanufacturing draws hundreds of millions in investments
![Biomanufacturing draws hundreds of millions in investments](https://antheia.bio/wp-content/uploads/2021/07/Industrial-Fermentation-2-1-jpg.webp)
Fundraising at Bota Bio, Genomatica, and Antheia signals an upshift for commercial-scale synthetic biology…